Paxlovid is safe, effective and doesn’t cause ‘rebound,’ FDA says

Paxlovid not linked to COVID rebound, FDA says

Clinical trial data has concluded that there is no clear association with a COVID-19 rebound.

Paxlovid not linked to COVID rebound, FDA says

Clinical trial data has concluded that there is no clear association with a COVID-19 rebound.

Paxlovid not linked to COVID rebound, FDA says

Clinical trial data has concluded that there is no clear association with a COVID-19 rebound.

Paxlovid not linked to COVID rebound, FDA says

Clinical trial data has concluded that there is no clear association with a COVID-19 rebound.

Paxlovid not linked to COVID rebound, FDA says

Clinical trial data has concluded that there is no clear association with a COVID-19 rebound.

Paxlovid not linked to COVID-19 rebound, FDA says ahead of meeting to consider drug's full approval

Over 8 million people in the U.S. have received Paxlovid, a combination of the drugs nirmatrelvir and ritonavir, since it became available under emergency use authorization in December 2021.